There's a head-to-head trial now. SURMOUNT-5 put tirzepatide directly against semaglutide for 72 weeks, and the margin wasn't close.
🔑 Key Takeaways
- The SURMOUNT-5 head-to-head trial showed tirzepatide (10-15mg) produced 20.2% average body weight loss vs 13.7% for semaglutide (2.4mg) over 72 weeks, a 47% relative improvement
- Over half of tirzepatide users (51.6%) lost 20% or more of their body weight, compared to 31.5% on semaglutide
- Tirzepatide activates two receptors (GLP-1 + GIP) while semaglutide activates only GLP-1. The GIP component directly enhances fat metabolism and may explain the performance gap
- Side effect profiles are comparable. Tirzepatide actually shows slightly lower rates of nausea, vomiting, and diarrhea than semaglutide in trial data
- Semaglutide has stronger cardiovascular outcome data (SELECT trial showed 20% reduction in major cardiovascular events). Tirzepatide's cardiovascular trial (SURPASS-CVOT) data is still emerging
- Cost is similar for branded versions ($900-$1,350/month). Compounded semaglutide is significantly cheaper ($99-$269/month). Compounded tirzepatide is harder to source after FDA crackdowns
This page covers the full comparison: mechanism, trial data, side effects, cost, and when each one makes more sense based on your specific situation.
The Head-to-Head Trial: SURMOUNT-5
This changed the conversation.
Before SURMOUNT-5, every comparison between tirzepatide and semaglutide was indirect: different trials, different populations, different timeframes. People would cite SURMOUNT-1 (tirzepatide) vs STEP 1 (semaglutide) and note the gap, but the comparison was always qualified with "these aren't head-to-head."
SURMOUNT-5 fixed that. The trial ran for 72 weeks, randomizing participants to either tirzepatide (escalated to 10-15mg weekly) or semaglutide (escalated to 2.4mg weekly). Same population. Same trial. Same endpoints. The results:
| Outcome | Tirzepatide (10-15mg) | Semaglutide (2.4mg) |
|---|---|---|
| Mean body weight loss | 20.2% | 13.7% |
| Achieved 20%+ weight loss | 51.6% | 31.5% |
| Achieved 25%+ weight loss | 31.6% | 16.1% |
| Relative improvement | 47% more weight loss with tirzepatide | |
The magnitude of the difference is notable. On average, tirzepatide produced about 6.5 percentage points more weight loss than semaglutide at maximum doses. For someone starting at 220 lbs, that's the difference between losing roughly 30 lbs (semaglutide) and losing roughly 44 lbs (tirzepatide).
How They Work: One Receptor vs Two
The mechanism explains the gap.
Semaglutide activates one receptor: GLP-1. This suppresses appetite, slows gastric emptying, stimulates insulin secretion, and acts on brain regions that control hunger and satiety. It does this well. The STEP trials demonstrated consistent 14-17% weight loss at the highest dose, and semaglutide has become the reference standard for GLP-1 therapy.
Tirzepatide activates two receptors: GLP-1 and GIP. Everything semaglutide does through GLP-1, tirzepatide also does. But the GIP component adds a separate mechanism: it directly enhances fat tissue metabolism, improves insulin sensitivity through pathways that GLP-1 alone doesn't reach, and appears to reduce muscle loss during weight loss better than GLP-1-only drugs.
The GIP receptor also seems to modulate the GI side effects that GLP-1 agonists are known for. This may explain why tirzepatide shows slightly lower nausea and vomiting rates than semaglutide despite producing more weight loss.
Think of it this way
Semaglutide makes you eat less by suppressing appetite and slowing digestion. Tirzepatide does the same thing, then adds a second mechanism that changes how your body processes and stores the fat you already have. Two levers instead of one.
Weight Loss Comparison: All the Data
Here's every major trial result side by side.
| Trial | Drug + dose | Duration | Avg weight loss |
|---|---|---|---|
| STEP 1 | Semaglutide 2.4mg | 68 weeks | 14.9% |
| STEP 2 (T2D) | Semaglutide 2.4mg | 68 weeks | 9.6% |
| SURMOUNT-1 | Tirzepatide 15mg | 72 weeks | 20.9% |
| SURMOUNT-2 (T2D) | Tirzepatide 15mg | 72 weeks | 14.7% |
| SURMOUNT-5 (head-to-head) | Tirzepatide 10-15mg | 72 weeks | 20.2% |
| SURMOUNT-5 (head-to-head) | Semaglutide 2.4mg | 72 weeks | 13.7% |
The pattern is consistent across every data set: tirzepatide outperforms semaglutide by roughly 40-50% in weight loss at maximum doses. The head-to-head SURMOUNT-5 data confirms what the cross-trial comparisons suggested.
Side Effects Compared
Surprisingly similar.
Both drugs produce GI side effects because both activate GLP-1 receptors that slow gastric emptying. The expectation was that tirzepatide, being more potent for weight loss, would produce worse side effects. The data shows the opposite for several categories:
| Side effect | Tirzepatide | Semaglutide |
|---|---|---|
| Nausea | ~40% | ~44% |
| Diarrhea | ~23% | ~30% |
| Vomiting | ~13% | ~24% |
| Constipation | ~18% | ~24% |
| Discontinuation from GI effects | ~4% | ~5% |
Tirzepatide has lower rates across the board. The GIP component may buffer the GI impact that pure GLP-1 activation produces. In practical terms, if you tolerated semaglutide, you'll very likely tolerate tirzepatide. If semaglutide's nausea was borderline manageable, tirzepatide may actually be easier.
Serious side effects (pancreatitis, gallbladder disease, thyroid concerns) carry the same FDA warnings for both drugs. The class-level risks are identical. For the full breakdown, see our Ozempic side effects and tirzepatide side effects pages.
Blood Sugar and Diabetes
Tirzepatide wins here too.
In the SURPASS trials (type 2 diabetes population), tirzepatide at 15mg reduced A1c by up to 2.5 percentage points, the largest reduction seen with any injectable diabetes medication. Semaglutide typically reduces A1c by 1.5 to 1.8 percentage points at its maximum dose.
The dual GLP-1/GIP mechanism provides better insulin secretion response and improved insulin sensitivity compared to GLP-1 alone. For people with type 2 diabetes or significant insulin resistance, tirzepatide's advantage extends beyond weight loss.
Cardiovascular Benefits
Semaglutide has the edge here.
The SELECT trial demonstrated that semaglutide 2.4mg reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in people with obesity and established cardiovascular disease. This is landmark data that no other weight loss medication has matched.
Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) showed non-inferiority to semaglutide for cardiovascular safety, but the dedicated outcomes trial data is not yet as mature. If you have established cardiovascular disease and the primary goal is cardiovascular risk reduction, semaglutide currently has stronger evidence.
Cost Comparison
Both are expensive at retail.
| Option | Monthly cost (approx.) |
|---|---|
| Wegovy (semaglutide, branded) | ~$1,350 |
| Ozempic (semaglutide, diabetes indication) | ~$900 |
| Zepbound (tirzepatide, weight loss) | ~$1,060 |
| Mounjaro (tirzepatide, diabetes) | ~$1,020 |
| Compounded semaglutide | $99-$269 |
| Compounded tirzepatide | $150-$350 (limited availability) |
Compounded semaglutide is the most affordable GLP-1 option right now. Compounded tirzepatide availability has been restricted by FDA enforcement actions against compounding pharmacies, making it harder to source than it was in 2024-2025. For the current landscape on sourcing tirzepatide through compounding, see our tirzepatide compounding pharmacy page.
Dosing Comparison
Both follow slow titration schedules.
| Phase | Semaglutide | Tirzepatide |
|---|---|---|
| Starting dose | 0.25mg weekly | 2.5mg weekly |
| First escalation (week 5) | 0.5mg | 5mg |
| Therapeutic range | 1mg-2.4mg | 5mg-15mg |
| Max approved dose | 2.4mg (Wegovy) | 15mg (Zepbound) |
| Time to max dose | 16-20 weeks | 20-32 weeks |
| Injection frequency | Once weekly | Once weekly |
Tirzepatide takes longer to reach maximum dose because it has more escalation steps. Both drugs emphasize slow titration to minimize GI side effects. Rushing the schedule with either one increases nausea, vomiting, and discontinuation rates. For detailed dosing protocols, see the tirzepatide dosing page and the semaglutide dosing page.
Which One Should You Choose?
It depends on what matters most.
Choose semaglutide when:
- Cost is the primary concern (compounded semaglutide is the most affordable GLP-1 option)
- Insurance covers Wegovy or Ozempic
- Your target weight loss is 10-15% (semaglutide is sufficient and proven)
- You have established cardiovascular disease (SELECT trial data is stronger)
- You want the longest real-world safety track record (Ozempic approved since 2017)
Choose tirzepatide when:
- Maximum weight loss is the priority (47% more effective than semaglutide in head-to-head data)
- You've plateaued on semaglutide and need more weight loss
- You have type 2 diabetes with significant A1c reduction needed (tirzepatide produces the largest A1c drops)
- Insulin resistance is a major factor (GIP component specifically improves insulin sensitivity)
- GI side effects were borderline on semaglutide (tirzepatide may be better tolerated)
Switching from Semaglutide to Tirzepatide
No washout period required.
If you've been on semaglutide and want to switch to tirzepatide, the standard protocol is to start tirzepatide at 2.5mg regardless of your previous semaglutide dose, then escalate on the standard 4-week schedule. The GLP-1 receptor adaptation from semaglutide carries over partially, but the GIP receptor component is new to your system, so starting at the lowest dose still makes sense for tolerability.
For the full switching protocol, see our switching from semaglutide to tirzepatide page.
Frequently Asked Questions
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Both semaglutide and tirzepatide require a prescription. Consult a licensed healthcare provider to determine which medication is appropriate for your individual health profile, medical history, and treatment goals.